PET/CT for Trop2 ADC Response Evaluation Cancers

Recruiting now

Conditions studied: Breast Cancer, Trop2, PET/CT

In brief

To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.

Key facts

Study ID

NCT07046689

Run by

The First Affiliated Hospital of Xiamen University

People needed

50

Starts

2024-11-01

Expected to finish

2026-12-31

Last updated by the study team

2025-07-15

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• adult patients (aged 18 years or order)
• histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports
• presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1
• willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee

You may not qualify if…

• Evidence of significantly impaired hepatic or renal function
• Estimated life expectancy of less than 3 months

Where it is running

• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.